Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double- blind study
Carregando...
Data
2012
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Purpose: To compare the effect of a single intravitreal injection of triamcinolone
acetonide and bevacizumab in reducing macular thickness, which was measured by
optical coherence tomography (OCT) in patients with diabetic macular oedema
(DMO).
Methods: The patients received a single intravitreal injection of 1.25 mg bev-
acizumab in one randomly selected eye and 4.0 mg triamcinolone acetonide in the
contralateral eye. Central foveal thickness measurement (CFT) with OCT was
taken at the initial visit and at the 4-week, 12-week and 24-week visits.
Results: Eleven patients (22 eyes) were enrolled and statistically analysed. CFT
reduced in the eyes treated with triamcinolone and those treated with bevacizumab
in weeks 4 and 12 (p < 0.05). At the 24-week follow-up, no significant difference
was noted, relative to the initial visit. Comparing the two groups treated with dif-
ferent drugs, a statistically significant difference in CFT in weeks 4 and 12 was
noted, with a more significant reduction in triamcinolone-treated eyes (p < 0.05).
Regarding visual acuity (VA), patients treated with triamcinolone had improvement
in VA at 4-week (p = 0.02) and 12-week follow-up (p = 0.01), while the group
treated with bevacizumab had VA improvement at 4 -week follow-up (p = 0.02).
Among the eyes treated with triamcinolone, intraocular pressure (IOP) measure-
ment of more than 21 mmHg was found in three eyes (27.3%).
Conclusions: Intravitreal triamcinolone proved to be more efficient in reducing
DMO, providing longer lasting visual improvement, relative to bevacizumab. Eyes
treated with triamcinolone had the highest percentage increase in IOP. Further
studies are needed to corroborate these findings.
Descrição
Palavras-chave
Bevacizumab, Complications from diabetes, Diabetic retinopathy, Visual acuity, Macular oedema ⁄ therapy, Triamcinolone acetonide ⁄ therapeutic use, Triamcinolone acetonide ⁄ administration & dosage
Citação
ISAAC, David Leonardo Cruvinel et al. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study. Acta Ophthalmologica, Hoboken, v. 90, p. 56-60, 2012.